Micron Biomedical, an Atlanta, GA-based life science company developing dissolvable microarray-based products, raised additional $3M in funding; extending its Series A to $17M.
The round was led by J2 Ventures. J2 Ventures Partner and former Chief Medical Officer of the Defense Innovation Unit, US Department of Defense, Dr. Matt Goldman, will join Micron’s board as an observer. Announced originally in November 2022, the Series A was led by Global Health Investment Corporation (GHIC) and LTS Lohmann with participation from GRA Venture Fund.
The extension will further support efforts to bring the company’s dissolvable microarray-based drug and vaccine products to markets globally.
Led by CEO Steven Damon, Micron Biomedical is focused on advancing dissolvable microarray-based, drug and vaccine administration technology. The patented microarray technology allows drugs and vaccines that today require cold storage and administration through injection to be self-administered or caregiver administered within minutes, without the need for refrigeration or administration by a skilled health professional.
Micron has partnered with or received funding from private and public pharmaceutical and biotech companies, the Bill & Melinda Gates Foundation, the Centers for Disease Control and Prevention (CDC), UNICEF, PATH and the Georgia Research Alliance.
FinSMEs
10/05/2023